Skip to content

Omics-based therapeutic decision-making in intermediate-risk prostate cancer

Omics-based therapeutic decision-making in intermediate-risk prostate cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00037424
Enrollment
192
Registered
2025-07-21
Start date
2026-12-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: Representation of differentially expressed genes depending on metastasis status and progression speed, identification of the tumor microenvironment, and development of multimodal prediction m

Sponsors

LMU Klinikum
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Prostate Cancer (ISUP 2 to 4) - Prostatectomy at LMU University Hospital

Exclusion criteria

Exclusion criteria: - Lymph node metastases or hematogenous metastases at first diagnosis

Design outcomes

Primary

MeasureTime frame
Representation of differentially expressed genes and pathways between primary tumors of metastatic and non-metastatic patients.

Secondary

MeasureTime frame
- Visualization of differentially expressed genes and pathways between fast and slow progressing patients - Identification of prostate cancer–specific tumor microenvironment subtypes (TCGA) and validation in spatial transcriptomic profiles of metastatic and non-metastatic patients - Development of multimodal predictive models for metastasis risk and progression velocity

Countries

Germany

Contacts

Public ContactChristian Trapp

LMU Klinikum

christian.trapp@med.uni-muenchen.de+4990440077520

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 10, 2026